Global Digital Therapy for Diabetes Market Strategic Research Report

Scope of the Report

The global Digital Therapy for Diabetes market size is predicted to grow from US$ 2,914 million in 2025 to US$ 8,077 million in 2032; it is expected to grow at a CAGR of 15.6% from 2026 to 2032.

Digital diabetes therapy refers to digital treatment solutions that utilize clinically validated software programs, artificial intelligence algorithms, mobile applications, cloud computing platforms, wearable devices, and digital health technologies to provide diabetes patients with digital treatment options including prevention, risk assessment, blood glucose management, behavioral intervention, lifestyle improvement, and disease treatment support. These products typically leverage multidimensional health data such as blood glucose levels, diet, exercise, sleep, and medication adherence to achieve long-term management of patients with type 2 diabetes, type 1 diabetes, and prediabetes through personalized feedback, intelligent reminders, remote monitoring, cognitive behavioral intervention (CBT), nutritional management, and AI predictive models. Unlike ordinary health management apps, digital therapy emphasizes evidence-based medicine validation, clinical effectiveness, and treatment goals. Some products can be used as medical intervention tools in conjunction with drug therapy, insulin therapy, and continuous glucose monitoring (CGM) systems.

The future of digital diabetes therapy is promising and transformative. By integrating artificial intelligence, wearable devices, and continuous glucose monitoring technology, it is driving a shift in diabetes management from the traditional "passive treatment" to a closed-loop model of "active intervention," enabling personalized, data-driven management from high-risk screening to complication prevention. Evidence-based medicine has already demonstrated that such interventions can effectively reduce patients' dependence on medication and even help some type 2 diabetes patients achieve long-term stable blood glucose levels after discontinuing medication. With the improvement of regulatory frameworks, the establishment of payment systems, and deep integration with clinical workflows, digital therapy is expected to become a core force in reshaping chronic disease management pathways, allowing precision medicine to truly benefit every patient.

This report presents a comprehensive overview of the global Digital Therapy for Diabetes market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Blood Glucose Control-Focused
• Lifestyle Intervention-Focused
• Medication-Assisted
• Complication Prevention-Focused
• Comprehensive Chronic Disease Management-Focused

Segment by Business Models

• B2B Model
• B2C Model
• B2B2C Model

Segment by players, this report covers

• Welldoc
• DarioHealth
• Omada Health
• Better Therapeutics
• Click Therapeutics
• Hedia
• Sweetch Health
• Wellthy Therapeutics
• Health2Sync
• Fitterfly
• Oviva
• Liva Healthcare
• Yidu Tech

Segment by Application

• Digital Therapeutics for Type 2 Diabetes
• Digital Therapeutics for Type 1 Diabetes
• Digital Therapeutics for Prediabetes

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Digital Therapy for Diabetes market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Digital Therapeutics for Type 2 Diabetes, Digital Therapeutics for Type 1 Diabetes, Digital Therapeutics for Prediabetes evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact